Abstract：
To explore serum levels of some bone turnover markers and the involvement of the Wnt signaling in CRPS-1. Query ID=\"Q1\" Text=\"Please check and confirm whether the edit made to the article title is in order.\" We conducted an observational study on patients with early CRPS-1 recruited before any treatment. Clinical measures were assessed together with biochemical evaluation. Values of sclerostin, DKK1, CTX-I, and P1NP were compared with sex-age-matched healthy controls (HCs). We enrolled 34 patients diagnosed with CRPS-1 (mean age 59.3 ± 10.6 years, Male/Female 10/24), median disease duration = 2 weeks (IQR 1-5); median VAS score = 76 (IQR 68-80). Foot localization was slightly more frequent than hand localization (18/16). No statistically significant difference was found between CRPS-1 patients and HCs for CTX-I (0.3 ± 0.1 ng/ml vs 0.3 ± 0.1, p = 0.140), while mean serum values of P1NP were significantly higher in CRPS-1 patients compared to HCs (70.0 ± 38.8 ng/ml vs 50.1 ± 13.6, p = 0.005). Mean levels of sclerostin and DKK1 were lower in CRPS-1 patients vs HCs (sclerostin 28.4 ± 10.8 pmol/l vs 34.1 ± 11.6, p = 0.004; DKK1 12.9 ± 10.8 pmol/l vs 24.1 ± 11.9, p = 0.001). No statistically significant difference was found for all biochemical assessments in a subgroup of fracture-induced CRPS-1. No statistically significant differences were observed according to disease localization, disease duration, presence of hyperalgesia, allodynia, sudomotor alterations, and mild or moderate/severe swelling. No significant correlation emerged between sclerostin, DKK1 levels, baseline VAS score, or McGill Pain Questionnaire score. Bone involvement in early CRPS-1 does not seem to rely on increased osteoclast activity. Conversely, a serum marker of bone formation resulted increased. Both Sclerostin and DKK1 showed decreased values, probably suggesting a widespread osteocyte loss of function.Trial registration number: Eudract Number: 2014-001156-28.
摘要：
探讨CRPS-1中某些骨转换标志物的血清水平和Wnt信号通路的参与。查询ID=\"Q1\"Text=\"请检查并确认对文章标题所做的编辑是否正确。“我们对任何治疗前招募的早期CRPS-1患者进行了观察性研究。临床措施与生化评估一起进行评估。硬化蛋白的值，DKK1CTX-I,将P1NP与性别年龄匹配的健康对照（HCs）进行比较。我们招募了34例诊断为CRPS-1的患者（平均年龄59.3±10.6岁，男/女10/24),中位病程=2周(IQR1-5);中位VAS评分=76(IQR68-80).脚定位比手定位稍微更频繁(18/16)。对于CTX-I，CRPS-1患者和HCs之间无统计学差异（0.3±0.1ng/mlvs0.3±0.1，p=0.140），而CRPS-1患者的P1NP平均血清值显着高于HCs（70.0±38.8ng/mlvs50.1±13.6，p=0.005）。CRPS-1患者的硬化蛋白和DKK1的平均水平低于HCs（硬化蛋白28.4±10.8pmol/lvs34.1±11.6，p=0.004；DKK112.9±10.8pmol/lvs24.1±11.9，p=0.001）。在骨折诱导的CRPS-1亚组中，所有生化评估均未发现统计学上的显着差异。根据疾病定位没有观察到统计学上的显著差异,疾病持续时间,存在痛觉过敏，异常性疼痛,sudomotor改变，轻度或中度/重度肿胀。硬化蛋白之间没有出现明显的相关性，DKK1电平,基线VAS评分,或麦吉尔疼痛问卷评分。早期CRPS-1的骨参与似乎并不依赖于破骨细胞活性的增加。相反，骨形成的血清标志物增加。硬化蛋白和DKK1均显示出下降的值，可能提示骨细胞功能广泛丧失。试用注册号：Eudract编号：2014-001156-28。
